GKV Capital Management Co. Inc. Purchases New Holdings in Edwards Lifesciences Co. (NYSE:EW)

GKV Capital Management Co. Inc. acquired a new position in Edwards Lifesciences Co. (NYSE:EW) during the fourth quarter, Holdings Channel.com reports. The institutional investor acquired 12,295 shares of the medical research company’s stock, valued at approximately $910,000.

Other institutional investors have also added to or reduced their stakes in the company. Vanguard Group Inc. raised its holdings in shares of Edwards Lifesciences by 10.4% in the fourth quarter. Vanguard Group Inc. now owns 69,132,036 shares of the medical research company’s stock worth $5,117,845,000 after buying an additional 6,537,494 shares during the period. Wellington Management Group LLP increased its stake in Edwards Lifesciences by 5.3% in the fourth quarter. Wellington Management Group LLP now owns 33,210,879 shares of the medical research company’s stock worth $2,458,601,000 after purchasing an additional 1,678,154 shares during the period. Geode Capital Management LLC lifted its position in shares of Edwards Lifesciences by 0.9% during the fourth quarter. Geode Capital Management LLC now owns 13,647,341 shares of the medical research company’s stock worth $1,007,520,000 after purchasing an additional 126,194 shares during the last quarter. Fisher Asset Management LLC boosted its stake in shares of Edwards Lifesciences by 7.7% during the fourth quarter. Fisher Asset Management LLC now owns 9,775,276 shares of the medical research company’s stock valued at $723,664,000 after purchasing an additional 696,965 shares during the period. Finally, Norges Bank bought a new position in shares of Edwards Lifesciences in the fourth quarter worth about $610,895,000. Institutional investors own 79.46% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have commented on the stock. Evercore ISI dropped their target price on shares of Edwards Lifesciences from $75.00 to $73.00 and set an “in-line” rating on the stock in a research note on Wednesday, February 12th. Piper Sandler raised their price objective on Edwards Lifesciences from $70.00 to $73.00 and gave the stock a “neutral” rating in a report on Wednesday, February 12th. Truist Financial decreased their target price on Edwards Lifesciences from $78.00 to $75.00 and set a “hold” rating for the company in a research report on Friday, April 11th. Barclays increased their price target on Edwards Lifesciences from $88.00 to $90.00 and gave the stock an “overweight” rating in a research report on Thursday, February 13th. Finally, Canaccord Genuity Group upped their price objective on shares of Edwards Lifesciences from $68.00 to $71.00 and gave the stock a “hold” rating in a research note on Thursday, February 13th. One investment analyst has rated the stock with a sell rating, fourteen have given a hold rating and ten have given a buy rating to the company’s stock. According to MarketBeat, Edwards Lifesciences currently has a consensus rating of “Hold” and an average target price of $78.55.

Insider Buying and Selling at Edwards Lifesciences

In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 9,500 shares of the stock in a transaction on Monday, April 14th. The stock was sold at an average price of $69.81, for a total transaction of $663,195.00. Following the sale, the vice president now owns 47,206 shares in the company, valued at approximately $3,295,450.86. This represents a 16.75 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Bernard J. Zovighian sold 6,164 shares of the business’s stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $69.51, for a total transaction of $428,459.64. Following the completion of the transaction, the chief executive officer now directly owns 59,083 shares of the company’s stock, valued at approximately $4,106,859.33. This represents a 9.45 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 71,853 shares of company stock valued at $5,163,062. Insiders own 1.29% of the company’s stock.

Edwards Lifesciences Trading Up 0.7 %

NYSE EW opened at $71.29 on Thursday. The company has a quick ratio of 2.89, a current ratio of 3.46 and a debt-to-equity ratio of 0.06. The stock has a market capitalization of $41.91 billion, a P/E ratio of 10.23, a P/E/G ratio of 4.82 and a beta of 1.15. Edwards Lifesciences Co. has a 52-week low of $58.93 and a 52-week high of $95.25. The firm has a 50-day moving average price of $71.29 and a 200 day moving average price of $70.76.

Edwards Lifesciences (NYSE:EW) last issued its earnings results on Tuesday, February 11th. The medical research company reported $0.59 EPS for the quarter, topping the consensus estimate of $0.55 by $0.04. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. Equities research analysts expect that Edwards Lifesciences Co. will post 2.45 EPS for the current year.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.